Skip to main content
Premium Trial:

Request an Annual Quote

PGXL Labs Adopts AutoGenomics' Infiniti System for Warfarin, CYP450 Testing


This story was originally posted on April 1.

PGXL Laboratories will offer warfarin and CYP450 2C19 testing on AutoGenomics' Infiniti system, the companies announced this week.

PGXL, a Louisville, Ky.-based pharmacogenomics services provider, also plans to introduce other AutoGenomics assays, such as its KRAS-BRAF test, in the future.

PGXL offers pharmacogenetic testing and interpretive services in its US Clinical Laboratory Improvement Acts-compliant facility. It also performs contract research for manufacturers of pharmaceuticals and medical equipment.

AutoGenomics' Infiniti platform makes use of the Vista, Calif.-based firm's BioFilmChip microarray technology, which consists of multiple layers of hydrogel matrices about 10 µm thick on a polyester solid support. AutoGenomics' warfarin and CYP450 2C19+ tests, in addition to several others, have been cleared by the US Food and Drug Administration for clinical use. The company is discussing additional submissions with the agency, including its KRAS and BRAF assay (BAN 1/25/2011).

Mark Linder, executive vice president of operations at PGXL, cited AutoGenomics' "comprehensive menu of molecular applications in the pharmacogenetics arena" as a reason why the testing company adopted the Infiniti platform.

Ram Vairavan, senior vice president of AutoGenomics, said that its array technology "allows us to rapidly develop new test applications to meet the evolving needs in companion diagnostic testing and enable PGXL Labs to expand the array of personalized medicine tests."

Further details of the deal were not discussed.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.